<DOC>
	<DOCNO>NCT01332721</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability determine recommend Phase 2 dose TRC105 add standard dose bevacizumab patient advance solid tumor bevacizumab indicate .</brief_summary>
	<brief_title>Study TRC105 Combined With Standard-Dose Bevacizumab Advanced Solid Tumors Which Bevacizumab Indicated</brief_title>
	<detailed_description>Bevacizumab monoclonal antibody vascular endothelial growth factor ( VEGF ) inhibit angiogenesis extends survival patient wide variety solid tumor type . TRC105 , monoclonal antibody CD105 , novel angiogenesis inhibitor complement bevacizumab preclinical model . Together , antibody may result effective angiogenesis inhibition improve clinical efficacy see bevacizumab alone . The purpose study evaluate safety tolerability determine recommend Phase 2 dose TRC105 add standard dose bevacizumab patient advance solid tumor bevacizumab indicate .</detailed_description>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Histologically proven advance metastatic solid cancer 2 . Measurable disease , evaluable disease elevation relevant soluble tumor marker ( e.g. , CEA , PSA , CA125 ) 3 . Age 18 year old 4 . ECOG performance status 0 1 5 . Resolution acute AEs result prior cancer therapy NCI CTCAE Grade ≤ 1 baseline ( except alopecia ) 6 . Adequate organ function 7 . Willing able consent self participate study 1 . Prior treatment TRC105 2 . Serious doselimiting toxicity relate prior bevacizumab 3 . Current treatment another therapeutic clinical trial 4 . Receipt investigational agent within 28 day start study treatment 5 . Prior surgery ( include open biopsy ) within 28 day start study treatment 6 . Prior radiation therapy systemic therapy within 21 day start study treatment 7 . Minor surgical procedure fine needle aspiration , Mediport placement core biopsy within 7 day study treatment 8 . Uncontrolled chronic hypertension define systolic &gt; 140 diastolic &gt; 90 despite optimal therapy ( initiation adjustment BP medication prior study entry allow provided average 3 BP reading visit prior enrollment &lt; 140/90 mm Hg ) 9 . Symptomatic pericardial pleural effusion 10 . Uncontrolled peritoneal effusion require paracentesis frequently every 2 week 11 . History brain involvement cancer , spinal cord compression , carcinomatous meningitis , new evidence brain leptomeningeal disease ( except expansion cohort MTD brain metastasis primary brain tumor eligible ) 12 . Angina , MI , symptomatic congestive heart failure , cerebrovascular accident , transient ischemic attack , arterial embolism , pulmonary embolism , DVT , PTCA CABG within past 6 month 13 . Active bleed pathologic condition carry high risk bleed 14 . Thrombolytic anticoagulant use ( except maintain i.v . catheter ) within 10 day prior first day study therapy 15 . Cardiac dysrhythmias NCI CTCAE Grade ≥ 2 within last 28 day 16 . Known active viral nonviral hepatitis 17 . Centrally locate nonsmall cell lung cancer ( regardless histologic subtype ) , nonsmall cell lung cancer squamous histology . 18 . History hemorrhage hemoptysis ( &gt; ½ teaspoon bright red blood ) within 6 month start study treatment 19 . Open wound unhealed fracture within 28 day start study treatment 20 . History peptic ulcer disease erosive gastritis within past 6 month , unless treat condition complete resolution document esophagogastroduodenoscopy ( EGD ) within 28 day start study treatment 21 . Known human immunodeficiency virus ( HIV ) acquire immunodeficiency syndrome ( AIDS ) relate illness 22 . Pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>TRC105</keyword>
	<keyword>CD105</keyword>
	<keyword>Endoglin</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Avastin</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>